Biolegend, 947803, Ultra-LEAF™ Purified anti-human CD273 (B7-DC, PD-L2) Antibody, 100μg

PD-L2 is a type I transmembrane protein of 273 amino acids, and it is a member of the B7 family. Human PD-L2 has 70% amino acid identity to its mouse orthologue. PD-L2 is the second ligand for PD-1, and its binding to PD-1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. PD-L2/PD-1 interaction suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Antibody blocking of PD-L2 on dendritic cells results in enhanced T cell proliferation and cytokine production. Interaction of PD-1 by PD-L1-Ig or PD-L2-Ig fusion protein has an inhibitory effect on proliferation and cytokine production during anti-CD3-mediated stimulation. PD-L2 is expressed in biopsies from human asthmatics and lungs of aeroallergen-treated mice and its expression correlates with the asthma severity. In vivo blockade of PD-L2 reduces the severity of allergen-driven airway hyperresponsiveness (AHR).  Blockage of PD-L2 induces the IL-12 production by DC; IL-12 may limit the severity of allergen-induced AHR antagonizing IL-13. In addition, blockade of PD-1 does not have effect on AHR; therefore, PD-L2 controls asthma severity in a PD-1 independent manner. PD-L2 binds to a second receptor, RGMb (repulsive guidance molecule b) which is expressed in lung interstitial macrophages and alveolar epithelial cells and is a co-receptor for bone morphogenetic proteins BMP2/4. Blockade of the RGMb/PD-L2 interaction significantly impaired the development of respiratory tolerance since the initial T cell expansion is inhibited.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant human PD-L2 (B7-DC, CD273)-Fc chimera
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Block - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by blocking the binding of 0.2 µg/mL biotinylated recombinant human PD-L2-Fc chimera (Cat. No. 785904) to 1 µg/mL immobilized recombinant human PD-1 (CD279)-Fc chimera (Cat. No. 785106). ND50 range: 0.2 - 1 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
RRID: AB_2894535 (BioLegend Cat. No. 947803) AB_2894535 (BioLegend Cat. No. 947804)
Structure: Dimer
Distribution: Immature dendritic cells, mature dendritic cells, subset of macrophages, placental endothelium, and medullary thymic epithelial cells
Function: Inhibits T cell mediated proliferation and cytokine production by CD4+ T cells. Regulate T cell responses. PD-L2 expression is up-regulated on antigen-presenting cells by IFN-γ.
Interaction: Antigen-stimulated T and B cells, regulatory T cells, follicular T and B cells, dendritic cells, monocytes
Ligand/Receptor: PD-1 (CD279), RGMb
Cell Type: Antigen-presenting cells, Dendritic cells, Epithelial cells, Macrophages, Plasma cells
Biology Area: Apoptosis/Tumor Suppressors/Cell Death, Cell Proliferation and Viability, Immunology
Molecular Family: CD Molecules, Immune Checkpoint Receptors, Soluble Receptors
Antigen References: Latchman Y, et al. 2001. Nat. Immunol. 2:261. Brown JA, et al. 2003. J. Immunol. 170:1257. Youngnak P, et al. 2003. Biochem. Biophys. Res. Commun. 307:672. Singh AK, et al. 2011. Allergy. 66:155. Lewkowich IP, et al. 2013. Mucosal. Immunol. 6:728. Xiao Y, et al. 2014. J. Exp. Med. 211:943. Bardhan K, et al. 2016. Front Immunol. 7:550.
Gene ID: 80380
UniProt: View information about CD273 on UniProt.org
Clone: A20050B
Regulatory Status: RUO
Other Names: CD273, Programmed cell death 1 ligand 2 (PD-L2), B7 dendritic cell molecule (B7-DC), Butyrophilin B7-DC, PDCD1 Ligand 2
Isotype: Rat IgG2b, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.